NCT00291213
Completed
Phase 3
Levetiracetam Treatment of Tardive Dyskinesia
Overview
- Phase
- Phase 3
- Intervention
- levetiracetam
- Conditions
- Tardive Dyskinesia
- Sponsor
- Yale University
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Abnormal Involuntary Movement Scale (AIMS) Total Score
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.
Investigators
Eligibility Criteria
Inclusion Criteria
- •meet Glazer Morgenstern criteria for TD -
Exclusion Criteria
- Not provided
Arms & Interventions
Levetiracetram Administration
Intervention: levetiracetam
Placebo
Intervention: placebo
Outcomes
Primary Outcomes
Abnormal Involuntary Movement Scale (AIMS) Total Score
Time Frame: 12 weeks
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's DiseaseParkinson's DiseaseNCT00307450Technische Universität Dresden34
Completed
Not Applicable
Levetiracetam for Treatment of Pain Associated With FibromyalgiaFibromyalgiaNCT00254657University of California, San Francisco66
Completed
Phase 3
A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)EpilepsyGeneralized Tonic-Clonic SeizuresNCT01228747UCB Japan Co. Ltd.361
Completed
Phase 2
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)Dyskinesia, Medication-InducedParkinson's DiseaseNCT02657681Fundación de investigación HM50
Not yet recruiting
Phase 3
Levetiracetam Prophylaxis in Brain Tumor Resection PilotSeizuresBrain TumorNCT05897658Hamilton Health Sciences Corporation70